The Janus kinase (JAK) inhibitor CTP-543 showed promising results in patients with moderate-to-severe alopecia areata according to interim results from a phase 2a study .
Alopecia areata is a poorly treatable autoimmune disease that affects women, men, and children of all ages. This chronic condition has a remarkable negative impact on quality of life and is associated with anxiety, depression, and other autoimmune conditions.
CTP-543 inhibits both JAK1 and JAK2 and is a modified version of the JAK inhibitor ruxolitinib, currently approved for the treatment of myelofibrosis and polycythemia vera. The double-blind, randomised, placebo-controlled, dose-ranging, phase 2 trial included 149 adult patients with moderate-to-severe alopecia areata. Entry criterion was an at least 50% hair loss as measured by Severity of Alopecia Tool (SALT) score. Patients were randomised to receive 4, 8, or 12 mg CTP-543 or placebo twice daily. Primary efficacy endpoint...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Acne highly influenced by climate, pollutants, and unhealthy diet Next Article
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.